Fortunately, elevating ROS levels could inhibit IGF1R bypass signaling and ERK/AKT/nuclear factor κB (NF-κB) signal pathways in the downstream, leading to high efficacy in inhibiting cell proliferation and overcoming bypass signal activation–related GEF resistance in NSCLC treatment (13). This evidence concerns the gene IGF1R and non-small cell lung carcinoma.